The synthesis route of haptens ( Figure S1 ), the full scan mass spectra of haptens ( Figure S2 ), UV absorption curve of conjugates ( Figure S3 ), optimization of icELISA working condition (Table S1, Figure S4 ), the isotype of mAb L02 ( Figure S5 ), HPLC-MS/MS calibration ( Figure S6 ), the linear regression analysis of between icELISA with HPLC-MS/MS ( Figure S7 ).
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Antigen preparation. The synthesis route and full scan mass spectra of hapten TYL-CHO was showed in figure S1, figure S2. Then the hapten were coupled to BSA as the immunogen and to OVA as the coating antigen by active ester method. The successful conjugations were confirmed by UV-visible spectra ( Figure S3 ). Optimization of icELISA working condition ( Figure S4 , Table S1 ). Several parameters in icELISA were optimized, including the concentration of antibody, coating antigens and HRP-IgG, working buffer (ionic strength, pH value and the concentration of tween-20) and reaction time. According to the chessboard titration and dose-response curves, the maximum absorbance value (Amax) and half maximal inhibitory concentration (IC50) were calculated.
The optical conditions were confirmed by Amax, Amax/IC50 and IC50. A condition with higher value of Amax/IC50 and lower value of IC50 were selected to use in assay. L02 (Figure S5) . The mAb L02 was diluted as 100 ng mL -1 by sample diluent. The commercial strip showed that multiple bands detected but the darkest band was the isotype of the most abundant antibody in the sample. 
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